In short
Clinical trials are currently underway to assess the effectiveness of a drug containing Anthoxanthum Odoratum, commonly known as sweet vernal grass, in treating allergies. This study focuses on using a mixture of grass pollens, including Anthoxanthum Odoratum, in a skin prick test solution to diagnose and potentially treat moderate to severe allergic rhinitis or rhinoconjunctivitis caused by house dust mite allergies. The research aims to provide valuable insights into new treatment options for allergy sufferers.
At a glance
- Study Type
- Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study
- Main Objective
- Assess efficacy of PURETHAL Mites Mixture in treating moderate to severe house dust mite-induced allergic rhinitis/rhinoconjunctivitis
- Treatment
- Subcutaneous immunotherapy with grass pollen mixture including Anthoxanthum Odoratum
- Duration
- Approximately 52 weeks
- Primary Endpoint
- Average daily Total Combined Rhinitis Score (TCRS) during last 8 weeks of treatment
- Key Inclusion Criteria
- Adults 18-65, moderate-severe HDM allergic rhinitis for 1+ year, positive skin prick test, minimum nasal symptom score
- Key Exclusion Criteria
- Severe immune disorders, active malignancies, moderate-severe asthma, history of anaphylaxis, recent/planned allergen immunotherapy
What is Anthoxanthum Odoratum?
Anthoxanthum odoratum, also known as sweet vernal grass, is a type of grass pollen extract used in allergy testing and treatment. It is one of several grass pollens included in a mixture used for diagnosing and treating grass pollen allergies.
Medical Use
Anthoxanthum odoratum is primarily used in the diagnosis and treatment of grass pollen allergies. It is part of a mixture of grass pollens used in skin prick tests and immunotherapy treatments for patients with allergic rhinitis (hay fever) or allergic rhinoconjunctivitis (affecting both nose and eyes) caused by grass pollen allergies.
Clinical Study
A clinical trial is being conducted to assess the effectiveness of a treatment containing Anthoxanthum odoratum and other grass pollens for adults with moderate to severe allergic rhinitis or rhinoconjunctivitis due to house dust mite allergy. This study aims to evaluate: The reduction in allergy symptoms and medication use Changes in quality of life for patients Safety and tolerability of the treatment Effects on asthma in patients who also have this condition
Administration
In the context of allergy testing, Anthoxanthum odoratum is typically administered as part of a skin prick test. This involves placing a drop of the allergen solution on the skin and then lightly pricking the skin to allow the solution to enter. For treatment, it may be given as part of subcutaneous immunotherapy (SCIT), which involves injections under the skin.
Potential Benefits
The potential benefits of treatments including Anthoxanthum odoratum for grass pollen allergies may include: Reduced allergy symptoms (such as sneezing, runny nose, and itchy eyes) Decreased need for allergy medications Improved quality of life Potential long-term reduction in allergy severity However, these benefits are still being studied in clinical trials.
Safety and Side Effects
As with any medical treatment, there may be potential side effects or risks associated with using Anthoxanthum odoratum in allergy testing or treatment. These could include: Local reactions at the site of skin prick tests or injections Allergic reactions, which in rare cases could be severe Potential effects on asthma symptoms in people who have both allergies and asthma The ongoing clinical trial is specifically evaluating the safety and tolerability of the treatment.
Who Can Use This Treatment?
Based on the clinical trial criteria, this type of treatment may be suitable for: Adults aged 18-65 with moderate to severe allergic rhinitis or rhinoconjunctivitis caused by grass pollen allergies Individuals with a confirmed grass pollen allergy through skin prick tests and blood tests People with or without mild asthma (as long as it's well-controlled) However, there are many factors that determine eligibility for this type of treatment, and it should only be used under the guidance of a qualified healthcare professional.